# Distribution and Drug‐Resistance Analysis of Uropathogens in Urinary Tract Infections

**Authors:** Weiyi Wu, Qiong Wu, Wenying Zhong, Lizhong Han

PMC · DOI: 10.1155/cjid/1700474 · The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien des Maladies Infectieuses et de la Microbiologie Médicale · 2026-02-22

## TL;DR

This study analyzed UTI-causing bacteria in Shanghai and found high drug resistance, especially to common antibiotics.

## Contribution

The study provides up-to-date regional data on uropathogen distribution and resistance patterns in Shanghai, China.

## Key findings

- Escherichia coli was the most common UTI pathogen, with high resistance to ampicillin, levofloxacin, and cefazolin.
- Klebsiella pneumoniae showed the highest resistance to ampicillin (97.3%) and levofloxacin (45.1%).
- Female sex, age >60 years, and hospitalization were significant risk factors for UTIs.

## Abstract

Urinary tract infections (UTIs) are a major global health concern with increasing antimicrobial resistance. Regional data on pathogen distribution and resistance patterns are essential for guiding empirical therapy. This study aimed to investigate the distribution and antimicrobial resistance profiles of UTI pathogens in Shanghai, China, and identify risk factors associated with UTIs.

A retrospective analysis was conducted on urine culture records from 61,450 patients suspected of UTIs, collected between January 1 and December 31, 2023, from two general hospitals in Shanghai. Pathogen identification and antimicrobial susceptibility testing were performed according to CLSI guidelines (2021). Multivariable logistic regression was used to analyze risk factors for UTIs.

Among 5671 confirmed UTI cases, Escherichia coli was the predominant pathogen (36.1%), followed by Enterococcus faecalis (11.2%) and Klebsiella pneumoniae (8.2%). E. coli exhibited high resistance to ampicillin (75.9%), levofloxacin (59.2%), and cefazolin (49.1%) but low resistance to carbapenems (1.0%). K. pneumoniae showed higher resistance rates, with the highest to ampicillin (97.3%) and levofloxacin (45.1%). Proteus spp. demonstrated significant resistance to ampicillin (66.7%) and fosfomycin (34.6%). Multivariable analysis identified female sex (OR = 1.55, 95% CI: 1.25–1.89), age > 60 years (OR = 2.60, 95% CI: 2.08–2.99), and hospitalization (OR = 2.49, 95% CI: 1.95–2.95) as significant risk factors for UTIs.

High antimicrobial resistance rates were observed among uropathogens in Shanghai, particularly to commonly used antibiotics. These findings highlight the need for region‐specific antibiotic stewardship programs and updated empirical treatment guidelines to combat rising resistance and improve clinical outcomes.

## Linked entities

- **Chemicals:** ampicillin (PubChem CID 6249), levofloxacin (PubChem CID 149096), cefazolin (PubChem CID 33255), carbapenems (PubChem CID 134085), fosfomycin (PubChem CID 441029)
- **Species:** Escherichia coli (taxon 562), Enterococcus faecalis (taxon 1351), Klebsiella pneumoniae (taxon 573)

## Full-text entities

- **Diseases:** K. pneumoniae infections (MESH:D011014), dysuria (MESH:D053159), sepsis (MESH:D018805), infectious diseases (MESH:D003141), cystitis (MESH:D003556), fever (MESH:D005334), urinary tract abnormalities (MESH:D014570), renal pyelonephritis (MESH:D011704), flank pain (MESH:D021501), urinary retention (MESH:D016055), UTI (MESH:D014552), calculi (MESH:D002137), infection (MESH:D007239), urethritis (MESH:D014526), chronic renal failure (MESH:D007676), Klebsiella infections (MESH:D007710), bacteremia (MESH:D016470), chills (MESH:D023341)
- **Chemicals:** ceftazidime (MESH:D002442), carbapenems (MESH:D015780), glycopeptide (MESH:D006020), vancomycin (MESH:D014640), Levofloxacin (MESH:D064704), cefazolin (MESH:D002437), meropenem (MESH:D000077731), cefepime (MESH:D000077723), ampicillin/sulbactam (MESH:C035444), ampicillin (MESH:D000667), imipenem (MESH:D015378), gentamicin (MESH:D005839), cefuroxime (MESH:D002444), aztreonam (MESH:D001398), fosfomycin (MESH:D005578), tetracycline (MESH:D013752), penicillin (MESH:D010406), nitrofurantoin (MESH:D009582), sulfamethoxazole (MESH:D013420), fluoroquinolones (MESH:D024841), ciprofloxacin (MESH:D002939), tigecycline (MESH:D000078304), cephalosporins (MESH:D002511), piperacillin/tazobactam (MESH:D000077725), ceftriaxone (MESH:D002443)
- **Species:** Citrobacter freundii (species) [taxon 546], Streptococcus agalactiae (species) [taxon 1311], Enterococcus faecalis (species) [taxon 1351], Fungi (kingdom) [taxon 4751], Enterococcus faecium (species) [taxon 1352], Escherichia coli (E. coli, species) [taxon 562], Candida tropicalis (species) [taxon 5482], Corynebacterium (genus) [taxon 1716], Candida albicans (species) [taxon 5476], Klebsiella pneumoniae (species) [taxon 573], Staphylococcus epidermidis (species) [taxon 1282], Homo sapiens (human, species) [taxon 9606], Proteus mirabilis (species) [taxon 584], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Nakaseomyces glabratus (species) [taxon 5478], Pseudomonas aeruginosa (species) [taxon 287]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12927959/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12927959/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12927959/full.md

---
Source: https://tomesphere.com/paper/PMC12927959